Mankind Pharma reports 55% YoY growth in PAT for Q3 FY24
Revenue from Operations stood at Rs. 2,607 crore, 25% YoY growth. Domestic revenue at Rs. 2,400 crore, 20% YoY growth and export revenue at Rs. 207 crore, 118% YoY growth
Revenue from Operations stood at Rs. 2,607 crore, 25% YoY growth. Domestic revenue at Rs. 2,400 crore, 20% YoY growth and export revenue at Rs. 207 crore, 118% YoY growth
Exblifeb demonstrates remarkable efficacy in treating complicated Urinary Tract Infections (cUTI), pneumonia
The company will be preferred business partner for VPPL in terms of sourcing and supplying key raw materials
GC1130A has previously achieved notable milestones by securing both RPDD and ODD from the U.S. FDA in January 2023
Tatva Chintan Pharma Chem has reported total income of Rs. 85.41 crores during the period ended December 31, 2023
The receipt of this permission paves way for the launch of Andexanet alfa powder for solution for infusion 200 mg (Andexxa) in India
Glenmark Life Sciences will manufacture API in the therapeutic area of urinary anti-spasmodic, to supply to the global innovator
Agreed Price of US$43 per share to deliver 48% premium to unaffected price on May 25, 2023
The bold, dynamic, and new logo unveiled in this process captures the essence of the 'Better Together' theme
Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa
Subscribe To Our Newsletter & Stay Updated